Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01729559 · ClinicalTrials.gov registry record · Phase 4
Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin
A Phase 4 study, sponsored by Scripps Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 495
- Enrollment target
NCT01729559: Completed Phase 4 study, sponsored by Scripps Health.
NCT01729559 is a Phase 4 study that has completed, run by Scripps Health. The registered enrollment target is 495 participants, roughly in line with the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01729559, a Phase 4 study, has completed, sponsored by Scripps Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 495 participants
- Enrollment target
Study Summary
The rate of venous thromboembolic events in trauma patients at high risk for deep vein thrombosis and pulmonary embolism receiving low dose unfractionated heparin every 8 hours will be equivalent or less than a similar group of patients given a standard every 12 hour dose of low molecular weight heparin.
Primary Outcome
Patients will have a bilateral lower extremity duplex ultrasound performed by a registered vascular technologist twice per week if the patient is in the ICU, or once per week if the patient is on the trauma ward. All of the deep veins from the external iliac to and including the calf veins will be interrogated. Diagnosis of deep vein thrombosis (DVT) will be defined as absence of complete vein compressibility, presence of an echogenic thrombus within the vein, absence of color flow characteristi
Interventions
- DRUG 5000 Units unfractionated Heparin Q 8 hr
- DRUG 30mg enoxaparin Q12 hr
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 495 participants |
| Start Date | 2012-11 |
| Est. Completion | 2014-10 |
| Phase | Phase 4 |
What the finished NCT01729559 record still lists
NCT01729559 is an interventional study that assigns participants to a tested intervention. The registered 495 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which 5000 Units unfractionated Heparin Q 8 hr is the first listed.
NCT01729559 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01729559 about?
NCT01729559 is a clinical study titled "Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin". The rate of venous thromboembolic events in trauma patients at high risk for deep vein thrombosis and pulmonary embolism receiving low dose unfractionated heparin every 8 hours will be equivalent or less than a similar group of patients given a standard every 12 hour dose of low molecular weight hep...
What is the current status of trial NCT01729559?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 495 participants. The study started on 2012-11. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01729559?
The interventions under investigation include: 5000 Units unfractionated Heparin Q 8 hr (DRUG), 30mg enoxaparin Q12 hr (DRUG).
Who is sponsoring clinical trial NCT01729559?
This trial is sponsored by Scripps Health, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01729559's enrollment target sits among peer trials
495 178th of 2000 higher than 1,823 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03127267 · 495 participants · Phase 3
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
- NCT06400472 · 495 participants · Phase 1
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
- NCT05283720 · 496 participants · Phase 2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- NCT06417775 · 496 participants · Phase 3
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia